The FDA and Medicare continue to influence diagnostic test coverage and therapy approvals, shaping market dynamics. Proposed local coverage determinations by Medicare contractor MolDx for transplant diagnostics, such as those offered by CareDx, would restrict surveillance testing frequency and impose stricter validity requirements, causing a near 40% drop in CareDx's stock price. At the regulatory level, the FDA is releasing new draft guidance to assist sponsors in evaluating drug combinations' individual contributions, fostering better oncology development. Meanwhile, the U.K. government is unveiling a life sciences strategy aimed at reducing drug and device approval costs by 25% over the next decade.